Asimov Completes Biosimilar Antibody Cell Line Campaign with Kyungdong
Boston, MA, August 9, 2026 Asimov announced the successful completion of a cell line development campaign in collaboration with...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Boston, MA, August 9, 2026 Asimov announced the successful completion of a cell line development campaign in collaboration with...
WALTHAM, Mass., July 24, 2026 Nova Biomedical has announced the acquisition of certain assets of NanoCellect, a recognized developer...
RANCHO CORDOVA, Calif., June 23, 2026 SK pharmteco has introduced SKyvecâ„¢, a next-generation multimodal viral vector platform designed to...
HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 — AGC Biologics...
HUNTSVILLE, Ala. and KASSEL, Germany, May 20, 2026 Discovery Life Sciences has launched Luminos® Comprehensive, a next-generation IVDR-compliant clinical...
JERUSALEM, Israel, May 20, 2026 Scinai Immunotherapeutics Ltd. has announced the appointment of Eilon Elmalem as the new Site...
